drugset / Trial / NCT06544616

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616 ↗

Phase 2 Active not recruiting 55 enrolled Janssen Pharmaceutica N.V., Belgium
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.

Timeline

Start
2024-07-22
Primary completion
2026-12-22
Completion
2027-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64042056 Unknown — Intramuscular

Indications